{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:52:26Z","timestamp":1792705946432,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.phrs.2024.107074","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T02:12:21Z","timestamp":1705803141000},"page":"107074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,639 biologic users from the Italian VALORE project"],"prefix":"10.1016","volume":"200","author":[{"given":"Ylenia","family":"Ingrasciotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Spini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"L'Abbate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Sofia","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Carollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ientile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Isgr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cavazzana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Biasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian","family":"Ejlli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Belleudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Poggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Sapigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Puccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Ancona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Pollina Addario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Allotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Zanforlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tuccori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Gini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Trifir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2024.107074_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.phrs.2024.107074_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2024.107074_bib3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?,\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107074_bib4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2024.107074_bib5","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2024.107074_othref0005","unstructured":"Xeljanz (tofacitinib): increased risk of major adverse cardiovascular events and malignancies with use of tofacitinib relative to TNF-alpha inhibitors, (2021). https:\/\/www.ema.europa.eu\/en\/documents\/dhpc\/direct-healthcare-professional-communication-dhpc-xeljanz-tofacitinib-increased-risk-major-adverse-cardiovascular-events-and-malignancies-use-tofacitinib-relative-tnf-alpha-inhibitors_en.pdf (accessed May 15, 2023)."},{"key":"10.1016\/j.phrs.2024.107074_bib7","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107074_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2024.107074_bib9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/rheumatology\/kex394","article-title":"Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries","volume":"57","author":"Kilcher","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2024.107074_bib10","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/bjd.17849","article-title":"A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis","volume":"181","author":"Yiu","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.phrs.2024.107074_bib13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s40259-021-00498-3","article-title":"Large-scale postmarketing surveillance of biological drugs for immune-mediated inflammatory diseases through an Italian distributed multi-database healthcare network: the VALORE project","volume":"35","author":"Trifir\u00f2","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.phrs.2024.107074_bib14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/pds.3952","article-title":"Validity of ankylosing spondylitis diagnoses in the health improvement network","volume":"25","author":"Dubreuil","year":"2016","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.phrs.2024.107074_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98321-0","article-title":"Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases","volume":"11","author":"Convertino","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2024.107074_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00403-020-02101-1","article-title":"Psoriasis severity matters when dealing with all-cause mortality in psoriasis patients: a record linkage analysis in Northern Italy","volume":"313","author":"Pezzolo","year":"2021","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.phrs.2024.107074_bib17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/CLEP.S383738","article-title":"Testing of coding algorithms for inflammatory bowel disease identification, as indication for use of biological drugs, using a claims database from Southern Italy","volume":"15","author":"Ingrasciotta","year":"2023","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.phrs.2024.107074_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229973","article-title":"Real word evidence on rituximab utilization: combining administrative and hospital-pharmacy data","volume":"15","author":"Roberto","year":"2020","journal-title":"PLOS One"},{"key":"10.1016\/j.phrs.2024.107074_bib20","article-title":"Switching and discontinuation pattern of biologic disease-modifying antirheumatic drugs and tofacitinib for patients with rheumatoid arthritis in Taiwan","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107074_bib21","first-page":"1","article-title":"Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis","volume":"157","author":"Gisondi","year":"2022","journal-title":"Ital. J. Dermatol. Venerol."},{"key":"10.1016\/j.phrs.2024.107074_bib22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s13555-017-0208-z","article-title":"Certolizumab pegol in the treatment of psoriasis and psoriatic arthritis: preliminary real-life data","volume":"7","author":"Dattola","year":"2017","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.phrs.2024.107074_bib23","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/art.40508","article-title":"Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database","volume":"70","author":"Clowse","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2024.107074_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/ecco-jcc\/jjac108","article-title":"Effectiveness and safety of ustekinumab in elderly patients with Crohn\u2019s disease: real world evidence from the ENEIDA registry","volume":"17","author":"Casas-Deza","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.phrs.2024.107074_bib25","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s10620-022-07770-8","article-title":"Ustekinumab and vedolizumab are equally safe and effective in elderly Crohn\u2019s disease patients","volume":"68","author":"Gebeyehu","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.phrs.2024.107074_bib26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/apt.16923","article-title":"Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study","volume":"56","author":"Pugliese","year":"2022","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2024.107074_bib27","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/ibd\/izab163","article-title":"Efficacy of vedolizumab in a nationwide cohort of elderly inflammatory bowel disease patients","volume":"28","author":"Khan","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2024.107074_bib28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.mcna.2011.11.003","article-title":"Age as a risk factor","volume":"96","author":"Dhingra","year":"2012","journal-title":"Med Clin. North Am."},{"key":"10.1016\/j.phrs.2024.107074_bib29","unstructured":"National Diabetes fact sheet, 2011, (n.d.). https:\/\/stacks.cdc.gov\/view\/cdc\/13329 (accessed May 15, 2023)."},{"key":"10.1016\/j.phrs.2024.107074_bib30","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s10067-022-06478-4","article-title":"Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study","volume":"42","author":"Ingrasciotta","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.phrs.2024.107074_bib31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107074_bib32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/apt.16436","article-title":"Superior treatment persistence with ustekinumab in Crohn\u2019s disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the persistence Australian national IBD cohort (PANIC) study","volume":"54","author":"Ko","year":"2021","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2024.107074_bib33","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/2050640620948802","article-title":"Sicilian network for inflammatory bowel disease (SN-IBD), effectiveness and safety of vedolizumab in biologically na\u00efve patients: a real-world multi-centre study","volume":"8","author":"Macaluso","year":"2020","journal-title":"U. Eur. Gastroenterol. J."},{"key":"10.1016\/j.phrs.2024.107074_bib34","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1016\/S2666-7568(22)00186-6","article-title":"Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43\u2008895 trials and 5\u2008685\u2008738 individuals across 989 unique drugs and 286 conditions in England","volume":"3","author":"Tan","year":"2022","journal-title":"Lancet Healthy Longev."},{"key":"10.1016\/j.phrs.2024.107074_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41746-020-0277-8","article-title":"Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations","volume":"3","author":"Averitt","year":"2020","journal-title":"Npj Digit. Med."},{"key":"10.1016\/j.phrs.2024.107074_bib36","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/archinternmed.2011.33","article-title":"Age-based exclusions from cardiovascular clinical trials: implications for elderly individuals (and for all of us): comment on \u201cthe persistent exclusion of older patients from ongoing clinical trials regarding heart failure,\u201d","volume":"171","author":"Gurwitz","year":"2011","journal-title":"Arch. Intern Med."},{"key":"10.1016\/j.phrs.2024.107074_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-017-0328-3","article-title":"Choosing first-line biologic treatment for moderate-to-severe psoriasis: what does the evidence say?","volume":"19","author":"Amin","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.phrs.2024.107074_bib38","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.cgh.2012.02.004","article-title":"Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population","volume":"10","author":"Ha","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2024.107074_bib39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","article-title":"Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL","volume":"66","author":"Gordon","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.phrs.2024.107074_bib40","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1136\/annrheumdis-2013-203695","article-title":"Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension","volume":"73","author":"Keystone","year":"2014","journal-title":"Ann. Rheumtol. Dis."},{"key":"10.1016\/j.phrs.2024.107074_bib41","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2015.09.056","article-title":"Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis","volume":"74","author":"Paller","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.phrs.2024.107074_bib42","first-page":"kead183","article-title":"Paediatric rheumatology international trials organisation (PRINTO), ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis","author":"Vojinovi\u0107","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2024.107074_bib43","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1185\/03007995.2010.547575","article-title":"Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn\u2019s disease in children: REACH open-label extension","volume":"27","author":"Hyams","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.phrs.2024.107074_bib44","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","article-title":"Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis","volume":"58","author":"Lovell","year":"2008","journal-title":"Arthritis Rheumtol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824000185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824000185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:51:20Z","timestamp":1760914280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824000185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":41,"alternative-id":["S1043661824000185"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107074","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,639 biologic users from the Italian VALORE project","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107074"}}